Clinical trial · Interventional
PCA vs Non-PCA Intravenous Hydromorphone Titration for Severe Cancer Pain
Patient Controlled Analgesia (PCA) vs Non-PCA Intravenous Hydromorphone Titration for Severe Cancer Pain: A Prospective, Randomized, Controlled, Multi-center, Phase III Trial
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
A large number of studies have shown that patients feel more satisfied with hydromorphone in the pain management. and a systematic review found that hydromorphone may be better suited than morphine for titration of acute analgesia. However, current researches on intravenous opioid titration for cancer pain such as hydromorphone are relatively insufficient in China. Therefore, a prospective, multi-center, randomized controlled study is conducted to assess the efficacy and safety of comparing patient-controlled analgesia (PCA) versus non-PCA intravenous hydromorphone titration for severe cancer pain.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer Pain | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Hydromorphone | Drug | — | UNRESOLVED |
| PCA pump | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- PCA IV Hydromorphone titration
- description
- PCA titration using programmable pump: bolus hydromorphone at 0.5mg (for opioid intolerance) or hydromorphone dose equivalent to 10% to 20% of the total opioid taken in the previous 24 hours with a lockout time 15 min (for opioid tolerance) was administered by the patients educated. No basal infusion was set in the pump.Repeated assessment of NRS score with a interval of 15 minutes until stable pain control. Then Repeated assessment of NRS score with a interval of 1 hour. The titration will be done on the patient's request (manipulation by the patient himelf/herself) in 24hrs.
- interventionNames
- Drug: Hydromorphone
- Device: PCA pump
- type
- ACTIVE_COMPARATOR
- label
- non-PCA IV Hydromorphone titration
- description
- Non-PCA titration administered by a nurse or clinician: Initial hydromorphone doses were same with PCA titration. Repeated assessment of NRS score with a interval of 15 minutes until stable pain control. Then Repeated assessment of NRS score with a interval of 1 hour. The dose of hydromorphone increased by 50%-100% if pain unchanged or increased, or repeat same dose if pain decrease to 4-6. The titration will be done on the patient's request (manipulation by a nurse) in 24hrs.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: 1. With written informed consent signed voluntarily by patients themselves. 2. Cancer patients aged 18-70 years old. 3. Patients with cancer pain more than or equal to NRS 7 during previous 24 hours. 4. Patients who will not be treated with radiotherapy within 7 days prior to randomization and during study. 5. Patients who need chemotherapy, long term administration of hormone, targeted therapy, or bisphosphonates therapy should undergo a stable anti- tumor therapy prior to randomization. 6. Patients or his/her caregivers who are able to fill out the questionnaire forms. 7. Ability to correctly understand and cooperate with medication guidance of doctors and nurses. 8. Without a history of anaphylaxis of narcotic drugs. 9. Without psychiatric problems. 10. ECOG performance status ≤3. 11. Not participated in another drug clinical trial within one month before inclusion（including hydromorphone）. Exclusion Criteria: 1. Patients diagnosed with non-cancer pain or unexplained pain. 2. Patients suffered with post-op pain. 3. Patients having paralytic ileus. 4. Patients who have hypersensitivity to hydromorphone. 5. There are abnormal lab results, with obvious clinical significance, such as the creatinine ≥ 2 fold of upper limit of normal value, or ALT or AST ≥ 2.5 fold of upper limit of normal value (≥ 5 fold,to the patients with liver metastasis or primary liver cancer), or liver function of Child C grade. 6. Patients having a incoercible Nausea and vomiting. 7. Monoamine oxidase inhibitor (MAOI) was administrated two week before randomization. 8. Patients who are pregnant or lactating,who plans to be pregnant within one month after the trial（including male）. 9. Patients who are opioid abuse. 10. Patients who are alcohol abuse. 11. Patients who are cognitive dysfunction. 12. Patients having a severe psychotic depression. 13. Patients with any other medical condition or reason, in that investigator's opinion, makes the patient unable to participate in a clinical trial.
References
Publications (0)
Data not yet available